Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retifanlimab and Epacadostat in Recurrent Gliomas
NCT03532295Phase 2Completed
- Sponsor
- Washington University School of Medicine
- Start
- Apr 2020
- Primary completion
- Jul 2024
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of retifanlimab, epacadostat in glioblastoma (GBM), Gliosarcoma (GS), astrocytoma, glioma, sponsored by Washington University School of Medicine. Started Apr 2020; status: completed.
02
Drugs
retifanlimabepacadostat
03
Conditions
glioblastoma (GBM)Gliosarcoma (GS)astrocytomaglioma
Beyond the preview
Go deeper on NCT03532295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03532295.